Powered by

Baylor College of Medicine: Cancer Immunotherapy Clinical Study Approved for Phase 1

Jun 08, 2019 - Targeted News Service

The Baylor College of Medicine issued the following news release:

A cancer immunotherapy research group at Baylor College of Medicine has secured Investigational New Drug regulatory clearance through the FDA to perform phase I clinical studies in newly-diagnosed adult patients with glioblastoma (GBM), a highly lethal form of brain cancer with a five-year survival rate of less than 10 percent in most age groups.

The regulatory milestone is the second for Dr. William Decker's academic ...